期刊文献+

奥拉西坦与茴拉西坦治疗血管性痴呆疗效对比性研究 被引量:4

Olathe tanks and Hui raschig jotham treatment of vascular dementia curative effect comparative research
在线阅读 下载PDF
导出
摘要 目的对比研究奥拉西坦与茴拉西坦治疗血管性痴呆的临床疗效。方法选择96例血管性痴呆患者,随机分成两组,治疗组(奥拉西坦组)48例,给予奥拉西坦0.4g,3次/日;对照组(茴拉西坦组)48例,给予茴拉西坦0.2g,3次/日,两组疗程均为90d。所有患者均在治疗前和治疗后分别应用MMSE、ADL、NIHSS测评其疗效。对两组患者治疗前后MMSE、ADL、NIHSS评分变化采用t检验进行分析。结果奥拉西坦组患者MMSE、ADL、NIHSS评分改变显著优于对照组(P<0.05)。结论奥拉西坦能改善血管性痴呆患者的认知功能,且疗效优于茴拉西坦,无不良反应。 Objective To contrast research olathe tanks and Hui raschig jotham the clinical curative effect of the treatment of vascular dementia. Methods Choose 96 cases of vascular dementia patients, randomly divided into two groups, the treatment group (olathe jotham group) 48 cases, give olathe jotham 0.4 g, 3 times/day, Control group (Hui raschig jotham group) 48 cases, give Hui raschig jotham 0.2 g, 3 times/day, two groups of treatment are for 90 days. All patients were in before treatment and after treatment were applied MMSE and ADL, NIHSS evaluation its curative effect. The two groups of patients before and after treatment, MMSE ADL, NIHSS score changes were analyzed by t test. Results The tanzi olathe patients MMSE and ADL, NIHSS score change is significantly better than that in control group (P 〈 0.05). Conclusion 0lathe tanks can improve the cognitive function of patients with vascular dementia, and the curative effect is better than the Hui raschig jotham, no bad reaction.
出处 《中国卫生产业》 2013年第3期14-15,共2页 China Health Industry
关键词 痴呆 血管性 奥拉西坦 茴拉西坦 对比研究 Dementia Vascular Olathe Tampa Hui raschig Tampa Comparative study
  • 相关文献

参考文献4

二级参考文献9

共引文献33133

同被引文献49

  • 1朱雀,蔡云红.奥拉西坦治疗血管性痴呆的临床研究[J].激光杂志,2005,26(2):97-97. 被引量:3
  • 2潘华舫.奥拉西坦治疗血管性痴呆的疗效观察[J].现代中西医结合杂志,2006,15(15):2053-2054. 被引量:9
  • 3王淑贞,迟兆富,郭洪志,张镛,罗本燕,裴海涛,邢成名,孙瑞元.奥拉西坦治疗脑器质性综合征随机双盲对照多中心研究[J].中国药学杂志,2007,42(15):1194-1196. 被引量:13
  • 4Bousser MG, Chabriat H. Vascular dementia[J]. Bull Ac-ad Natl Med, 2012, 196(2):409.
  • 5RafFaitin C,Gin H,Empana JP. Metabolic syndrome andrisk for incident Alzheimer’s disease or vascular demen-tia :the Three-City Study[J]. Diabetes Care,2009,32(1):169.
  • 6Gorelick PB. Status of risk factors for dementia associatedwith stroke [J]. Stroke, 1997,28(2) : 459.
  • 7Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms[J]. Prog Neuropsychopharmacol Biol Psy- chiatry, 1989,13 Suppl: S77.
  • 8Gabryel B,Trzeciak HI,Pudeiko A,et al. Influence of pi-racetam and oxiracetam on the content of high-energyphosphates and morphometry of astrocytes in vitro [J], PolJ Pharmacol, 1999,51(6):485.
  • 9Hoggins JPT, Green S. Cochrane Handbook for systemat-ic Reviews of Interventions Verdion 5.1[EB/OL]. [2013-06-01]. http://www. Cochranehandbook.org.
  • 10Pepeu G, Spignoli G. Nootropic drugs and brain choliner- gic mechanisms[J]. Prog Neuropsychopharmacol Biol Psy- chiatry, 1989,13 Suppl: S77.

引证文献4

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部